Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients
- PMID: 16686650
- DOI: 10.1111/j.1528-1167.2006.00553.x
Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients
Abstract
Purpose: To assess the long-term evolution of Unverricht-Lundborg disease (ULD), especially concerning myoclonus, seizures, and EEG characteristics.
Methods: We retrospectively evaluated 20 patients (six women, 14 men; mean age, 37.9 years; range, 26-53 years) with ULD who had been closely followed up since the onset of the disease (mean age, 12.3 years; range, 6-17 years) for an average of 25.6 years (range, 13-41 years). ULD was confirmed by genetic tests in all. We used simplified myoclonus and seizure rating scales.
Results: The geographic origin of the patients was Northern Africa in nine, France in two, Italy in six, and mixed European in three. Three patients were severely handicapped, six led fully autonomous lives, and 11 required various degrees of social support. Myoclonus progressed only during the first 5 years of disease. Major seizures occurred in 19. Three patients had a single seizure, and eight became seizure free, whereas six had rare seizures, and two had frequent attacks. Overall, seizures became much less frequent after 10 years of evolution. EEG changes abated during follow-up: background activity remained stable or improved, spontaneous discharges disappeared, and photoparoxysmal responses were abolished in all patients but two.
Conclusions: This study shows that ULD progresses only over a limited period and stabilizes thereafter. This self-limited progression may be the consequence of age-related apoptosis of selected neuronal populations.
Similar articles
-
Long-term evolution of EEG in Unverricht-Lundborg disease.Epilepsy Res. 2007 Mar;73(3):219-27. doi: 10.1016/j.eplepsyres.2006.10.006. Epub 2006 Dec 8. Epilepsy Res. 2007. PMID: 17158032
-
Unverricht-Lundborg progressive myoclonus epilepsy in Oman.Pediatr Neurol. 2008 Apr;38(4):252-5. doi: 10.1016/j.pediatrneurol.2007.11.006. Pediatr Neurol. 2008. PMID: 18358403
-
Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.Epilepsia. 2004 Jun;45(6):678-81. doi: 10.1111/j.0013-9580.2004.56902.x. Epilepsia. 2004. PMID: 15144434 Clinical Trial.
-
Clinical picture of EPM1-Unverricht-Lundborg disease.Epilepsia. 2008 Apr;49(4):549-56. doi: 10.1111/j.1528-1167.2008.01546.x. Epub 2008 Mar 5. Epilepsia. 2008. PMID: 18325013 Review.
-
[Unverricht-Lundborg disease (PME1)].Rev Neurol (Paris). 2006 Sep;162(8-9):819-26. doi: 10.1016/s0035-3787(06)75084-6. Rev Neurol (Paris). 2006. PMID: 17028542 Review. French.
Cited by
-
Profile of brivaracetam and its potential in the treatment of epilepsy.Neuropsychiatr Dis Treat. 2015 Nov 30;11:2967-73. doi: 10.2147/NDT.S60849. eCollection 2015. Neuropsychiatr Dis Treat. 2015. PMID: 26664121 Free PMC article. Review.
-
Unverricht-Lundborg disease (EPM1) in Finland: A nationwide population-based study.Neurology. 2020 Dec 8;95(23):e3117-e3123. doi: 10.1212/WNL.0000000000010911. Epub 2020 Sep 17. Neurology. 2020. PMID: 32943486 Free PMC article.
-
The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.Seizure. 2019 Oct;71:247-257. doi: 10.1016/j.seizure.2019.08.012. Epub 2019 Aug 23. Seizure. 2019. PMID: 31476531 Free PMC article. Review.
-
Death in Unverricht-Lundborg disease.Neurol Sci. 2009 Aug;30(4):315-8. doi: 10.1007/s10072-009-0102-2. Epub 2009 Jun 5. Neurol Sci. 2009. PMID: 19499178
-
The network sustaining action myoclonus: a MEG-EMG study in patients with EPM1.BMC Neurol. 2016 Nov 7;16(1):214. doi: 10.1186/s12883-016-0738-5. BMC Neurol. 2016. PMID: 27821136 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical